LONG ACTING GCSF PROTEINS FOR TREATING NEUTROPENIA

描述：这是一项第二阶段的拨款申请，旨在进一步发展Long 用于治疗中性粒细胞减少症的G-CSF代理蛋白。它是由 博尔德生物技术公司乔治·N·考克斯博士，首席研究员。 研究人员指出，重组G-CSF在全球的销量超过 1998年为12亿美元。他们建议创造修饰的G-CSF蛋白质，这些蛋白质是 与天然粒细胞集落刺激因子相当或优于天然粒细胞集落刺激因子 在体内，但需要较少的频率剂量。他们的目标是拥有一个长期的 作用蛋白质，可以一周一次或每隔一周给药。在.期间 第一阶段，他们确定了G-CSF中可以在没有修改的情况下进行修改的位置 降低蛋白质的体外生物活性。在第二阶段，他们计划 生产足够量的修饰G-CSF蛋白，用于在 中性粒细胞减少的动物模型。他们认为，这些新的G-CSF 蛋白质将减少每个患者所需的G-CSF数量，改善患者 合规性和生活质量，并为以下方面节省大量成本 患者和医疗保健提供者。 建议的商业应用： 不可用

DESCRIPTION: This is a Phase II grant application to further develop long acting G-CSF proteins for the treatment of neutropenia. It is submitted by Bolder Biotechnology, Inc. George N. Cox, PhD, Principal investigator. The investigator notes the recombinant G-CSF has a worldwide sales in excess of $1.2 Billion in 1998. They propose to create modified G-CSF proteins that are equal to or superior than natural G-CSF in stimulating granulocyte formation in-vivo but would require less frequent dosing. Their goal is to have a long acting protein that could be given once a week or every other week. During Phase I they identified sites in the G-CSF that could be modified without reducing the proteins bio-activity in-vitro. During Phase II they plan to manufacture sufficient quantities of the modified G-CSF protein for testing in animal models with neutropenia. It is their contention that these novel G-CSF proteins will reduce the amount of G-CSF required per patient, improve patient compliance and quality of life, and result in considerable cost savings for patients and healthcare providers. PROPOSED COMMERCIAL APPLICATION: Not Available